伊立替康DEB-TACE已经显示出有希望的结果，RR（78%）和PFS（中位时间8个月）[1，2]，但副作用也让人比较担心[3]。 Martin 等人报告[4] 一组用伊立替康药物洗脱微球（Drug-Eluting Beads, Irinotecan ，DEBIRI）对标准全身化疗失败后转移性结直肠癌病人进行TACE的结果。N=50，中位伊立替康剂量100mg（100-200mg），中位治疗次数为2次（1-5次），1年的ORR 75%    ，DFS为11月，OS为19个月。1. Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res. 2006 Sep-Oct;26(5B):3793-5. 2. Aliberti C, Fiorentini G, Muzzio PC, Pomerri F, Tilli M, Dallara S, Benea G. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res. 2011 Dec;31(12):4581-7. 3. Martin RC, Howard J, Tomalty D, Robbins K, Padr R, Bosnjakovic PM, Tatum C. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol. 2010 Oct;33(5):960-6 4. Martin RC, Joshi J, Robbins K, Tomalty D, Bosnjakovik P, Derner M, Padr R, Rocek M, Scupchenko A, Tatum C. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2011 Jan;18(1):192-8. doi: 10.1245/s10434-010-1288-5. Epub 2010 Aug 26. |